Methylglyoxal Evaluation in Humans
CompletedNCT05350553
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The investigators will test the hypothesis that patients with low back pain associated with lumbar disc aberrancy will have elevated MGO-protein levels circulating in the blood that are comparable to patients with painful diabetic neuropathy.
Study details
- Official title
- A Cross-Sectional Trial of Methylglyoxylated-Protein Levels in Adults With Chronic Pain
- Conditions
- Type 2 Diabetes
- Neuropathy, Painful
- Chronic Low-back Pain
- Lumbar Disc Herniation
- Sponsor
- University of Kansas Medical Center
- Start date
- 2022-05-02
- Primary completion
- 2025-04-01
- Sex
- All
- Age range
- from 45 Years to 75 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Informed consent provided by the subject * Able to read/speak English * TYPE 2 DIABETES * All healthy inclusion criteria AND * Blood glucose levels \> 126 mg/dl * Diagnosed with neuropathy or experience painful numbness or tingling in their hands or feet * LOW BACK PAIN * All healthy inclusion criteria AND * Chronic (persistent pain lasting longer than 3 months) low back pain as a direct result of non-operative lumbar disc aberrancy (disc herniation, protrusion, or extrusion) * Aberrancy occurring within 12 months of pre-screening Exclusion Criteria: * Prisoner * Current clinically significant cardiac or neurological disease * Diagnosis of IBS, osteoarthritis, fibromyalgia, complex regional pain syndrome (CRPS), postherpetic neuralgia * Lumbar surgery due to disc aberrancy * Therapeutic spinal injections within the last 3 months (steroid, ablations, etc.) * Chronic use of steroids or non * steroidal anti-inflammatory drugs (NSAIDS) within 3 months of pre-screen * Past or present use of spinal cord stimulators
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05350553